BVS News and Press, Bioventus Inc. From 11/07/23

Bioventus Inc. (BVS) is expected to report $0.06 for Q3 2023

DURHAM, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before th...

2023-10-11 17:44:42 ET Summary Bioventus Inc. is attempting to move forward from disappointing results in recent years including the failed acquisition of "CartiHeal." The company expects growth to reaccelerate into 2024 as recent pricing pressures stabilize. We expect Biovent...

DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Confere...

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesda...

2023-08-17 10:07:42 ET Gainers: CervoMed ( CRVO ) +86% . Tivic Health Systems ( TIVC ) +34% . Jupiter Wellness ( JUPW ) +11% . NEXGEL ( NXGL ) +9% . Kamada ( KMDA ) +8% . Losers: Check-Cap ( CHEK ) -23% . ...

2023-08-15 14:26:44 ET Penny stocks provide a captivating opportunity for those aiming to profit in the stock market. The intrinsic risk and potential rewards associated with these stocks often lead to intense speculation and a quest for remarkable profits. It’s not uncommon to witne...

2023-08-12 13:56:08 ET Bioventus Inc. (BVS) Q2 2023 Results Conference Call August 08, 2023 08:30 AM ET Company Participants Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Conference Call Participants Chase Knickerbocker - Craig-H...

2023-08-08 07:37:58 ET Bioventus press release ( NASDAQ: BVS ): Q2 GAAP EPS of -$0.06 beats by $0.10 . Revenue of $137.1M (-2.3% Y/Y) beats by $7.87M . For further details see: Bioventus GAAP EPS of -$0.06 beats by $0.10, revenue of $137.1M beats by $7.87M

DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: Net Sales ...